Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition

We examined plasma concentrations of phyto-oestrogens in relation to risk for subsequent prostate cancer in a case–control study nested in the European Prospective Investigation into Cancer and Nutrition. Concentrations of isoflavones genistein, daidzein and equol, and that of lignans enterolactone and enterodiol, were measured in plasma samples for 950 prostate cancer cases and 1042 matched control participants. Relative risks (RRs) for prostate cancer in relation to plasma concentrations of these phyto-oestrogens were estimated by conditional logistic regression. Higher plasma concentrations of genistein were associated with lower risk of prostate cancer: RR among men in the highest vs the lowest fifth, 0.71 (95% confidence interval (CI) 0.53–0.96, \( P = 0.03 \)). After adjustment for potential confounders this RR was 0.74 (95% CI 0.54–1.00, \( P = 0.05 \)). No statistically significant associations were observed for circulating concentrations of daidzein, equol, enterolactone or enterodiol in relation to overall risk for prostate cancer. There was no evidence of heterogeneity in these results by age at blood collection or country of recruitment, nor by cancer stage or grade. These results suggest that higher concentrations of circulating genistein may reduce the risk of prostate cancer but do not support an association with plasma lignans.

Keywords: prospective; prostate cancer; plasma; isoflavone; lignan; genistein
incidence prostate cancer and 1042 matched control participants participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). We also examine associations with plasma concentrations of the lignans enterolactone and enterodiol, and evaluate the associations of isoflavones and lignans with risk subdivided by the stage of disease and other factors.

MATERIALS AND METHODS

Participants and data

Between 1992 and 2000, ~500,000 individuals (150,000 men) were recruited into EPIC from 23 centres in 10 European countries. The methods of recruitment and study design have been described in detail elsewhere (Riboli et al, 2002). The participants completed an extensive questionnaire on dietary and non-dietary factors at recruitment, and about 400,000 individuals (of whom 137,000 were men) also provided a blood sample. All participants gave written consent for the research, and approval for the study was obtained from the Internal Review Board of the International Agency for Research on Cancer (Lyon, France) and from the local ethics committees in the participating countries.

This study includes prostate cancer cases occurring after blood collection and individually matched male control participants from the eight participating countries, which recruited men: Denmark, Germany, Greece, Italy, the Netherlands, Spain, Sweden and the United Kingdom.

Follow-up for diagnosis of prostate cancer is provided through record linkage with population-based cancer registries in six of the participating countries: Denmark, Italy, the Netherlands, Spain, Sweden and the United Kingdom. In Germany and Greece, follow-up is active and is achieved through checks of insurance records and cancer and pathology registries, as well as through self-reported questionnaires; self-reported incident cancers are verified through medical records. Data on vital status in most EPIC study centres were collected from mortality registries at the regional or national level, in combination with data collected by active follow-up (Greece). The 10th Revision of the International Statistical Classification of Diseases, Injuries and Causes of Death was used, and cancer of the prostate was defined as code C61. For each EPIC centre, closure dates of the study period were defined as the latest dates of complete follow-up for both cancer incidence and vital status (dates varied between centres, from June 1999 to January 2003).

Case patients were men who developed prostate cancer after the date of blood collection and before the end of the study period, defined for each study centre by the latest date of follow-up. The cases with no available blood sample and those participants who had missing information on the date of the blood donation, or who had a history of another cancer (except non-melanoma skin cancer) at the time of diagnosis of the index case, were excluded. After these exclusions, laboratory measures for the current analysis were collected from each centre, where possible. A total of 675 cases from the eight participating countries, which case patients were matched to two control participants, from the eight participating countries, which recruited men:

Follow-up for diagnosis of prostate cancer is provided through record linkage with population-based cancer registries in six of the participating countries: Denmark, Italy, the Netherlands, Spain, Sweden and the United Kingdom. In Germany and Greece, follow-up is active and is achieved through checks of insurance records and cancer and pathology registries, as well as through self-reported questionnaires; self-reported incident cancers are verified through medical records. Data on vital status in most EPIC study centres were collected from mortality registries at the regional or national level, in combination with data collected by active follow-up (Greece). The 10th Revision of the International Statistical Classification of Diseases, Injuries and Causes of Death was used, and cancer of the prostate was defined as code C61. For each EPIC centre, closure dates of the study period were defined as the latest dates of complete follow-up for both cancer incidence and vital status (dates varied between centres, from June 1999 to January 2003).

Case patients were men who developed prostate cancer after the date of blood collection and before the end of the study period, defined for each study centre by the latest date of follow-up. The cases with no available blood sample and those participants who had missing information on the date of the blood donation, or who had a history of another cancer (except non-melanoma skin cancer) at the time of diagnosis of the index case, were excluded. After these exclusions, laboratory measures for the current analysis were available for 950 cases: 288 cases in Denmark, 201 in Germany, 9 in Greece, 62 in Italy, 25 in the Netherlands, 93 in Spain, 94 in Sweden and 178 in the United Kingdom.

Data on the stage and grade of disease at diagnosis were collected from each centre, where possible. A total of 675 cases (71.1%) had information on tumour stage; of these 475 (50.0%) were classified as localised (tumour (T)-node (N)-metastasis (M) = T1N0M0), 200 (21.1%) were classified as localised (T1N0M0), 181 (19.2%) were classified as localised (T1N0M0), 70 (7.6%) were classified as regional (T1N1M0), 30 (3.1%) were classified as regional (T1N1M0), 10 (1.0%) were classified as regional (T1N1M0), 5 (0.5%) were classified as regional (T1N1M0), and 0 (0.0%) were classified as regional (T1N1M0).

Follow-up for diagnosis of prostate cancer is provided through record linkage with population-based cancer registries in six of the participating countries: Denmark, Italy, the Netherlands, Spain, Sweden and the United Kingdom. In Germany and Greece, follow-up is active and is achieved through checks of insurance records and cancer and pathology registries, as well as through self-reported questionnaires; self-reported incident cancers are verified through medical records. Data on vital status in most EPIC study centres were collected from mortality registries at the regional or national level, in combination with data collected by active follow-up (Greece). The 10th Revision of the International Statistical Classification of Diseases, Injuries and Causes of Death was used, and cancer of the prostate was defined as code C61. For each EPIC centre, closure dates of the study period were defined as the latest dates of complete follow-up for both cancer incidence and vital status (dates varied between centres, from June 1999 to January 2003).

Case patients were men who developed prostate cancer after the date of blood collection and before the end of the study period, defined for each study centre by the latest date of follow-up. The cases with no available blood sample and those participants who had missing information on the date of the blood donation, or who had a history of another cancer (except non-melanoma skin cancer) at the time of diagnosis of the index case, were excluded. After these exclusions, laboratory measures for the current analysis were available for 950 cases: 288 cases in Denmark, 201 in Germany, 9 in Greece, 62 in Italy, 25 in the Netherlands, 93 in Spain, 94 in Sweden and 178 in the United Kingdom.

Data on the stage and grade of disease at diagnosis were collected from each centre, where possible. A total of 675 cases (71.1%) had information on tumour stage; of these 475 (50.0%) were classified as localised (tumour (T)-node (N)-metastasis (M) = T1N0M0), 200 (21.1%) were classified as localised (T1N0M0), 181 (19.2%) were classified as localised (T1N0M0), 70 (7.6%) were classified as localised (T1N0M0), 30 (3.1%) were classified as localised (T1N0M0), 10 (1.0%) were classified as localised (T1N0M0), 5 (0.5%) were classified as localised (T1N0M0), and 0 (0.0%) were classified as localised (T1N0M0).

Laboratory assays

Plasma samples were analysed for three isoflavones (genistein, daidzein and equol) and two lignans (enterolactone and enterodiol) using ultra performance liquid chromatography–tandem mass spectrometry in the HFL laboratory, Fordham, UK using an adaptation of an earlier published method (Grace et al, 2007). The laboratory personnel who conducted the assays were blinded to the case or control status of the participants. Plasma samples from each case–control set were assayed within the same batch and analysed on the same day. Three quality control plasma samples were inserted into each assay batch and analysed in duplicate.

The quality control samples contained concentrations of genistein, daidzein, equol, enterolactone and enterodiol, which reflected low, medium and high ranges of the calibration chart (0.1–500 ng ml–1, e.g. equivalent to 0.37–1850 nmol l–1 of genistein). The average intra-assay co-efficient of variation (CV) ranged from 3.1 (enterolactone) to 5.9% (equol). The average inter-assay CVs ranged from 4.1 (enterodiol) to 6.2% (equol).

The lower limit of quantification, equivalent to the lowest point in the calibration curve, was 0.1 ng ml–1 for each analyte (equivalent to 0.37 nmol l–1 of genistein, 0.39 nmol l–1 of daidzein, 0.41 nmol l–1 of equol, 0.34 nmol l–1 of enterolactone and 0.33 nmol l–1 of enterodiol); the percentage of samples in which levels were not detectable was 16% for genistein, 13% for daidzein, 43% for equol, 2% for enterolactone and 16% for enterodiol. For individuals with levels below this limit, phyto-oestrogen concentrations were imputed at 0.05 ng ml–1 (equivalent to ~0.2 nmol l–1).

Statistical analysis

Statistical analyses were carried out with the Stata 9 statistical software package (StataCorp, 2005). All tests of statistical significance were two-sided, and P-values below 0.05 were considered significant.

Differences in baseline characteristics of cases and controls were compared using conditional logistic regression models for categorical variables or a weighted paired t-test for continuous variables, comparing the value for the case with the value in the matched control participant, or the mean of the values in controls when there were two matched controls in a set (Rosner, 1982).

Spearman’s rank correlation coefficients were calculated to assess the correlations between plasma levels of phyto-oestrogens among control participants.

Conditional logistic regression models were applied to calculate the relative risks (RRs) (odds ratios) for prostate cancer in relation to fifths of genistein, daidzein, enterolactone and enterodiol concentrations, using cut points defined by the quintiles among the control participants for all centres combined and using the lowest category as reference. For equol, given the high proportion of values below the lower limit of quantification and an interest in the
comparison between non-producers and producers, the grouping was as follows: not detected (non-producers), and those with detectable levels of equol (producers) divided into fourths using cut points defined by the quartiles of equol concentration among control participants for all centres combined. Likelihood ratio tests were used to assess heterogeneity, and tests for linear trend were obtained using a continuous variable with values equal to the median concentration within each quintile of plasma phyto-oestrogen concentration.

To examine the effects of potential confounders (other than the matching criteria, controlled for by design), the analyses were repeated including additional variables in the logistic regression models. These variables were smoking (never, past and present), body mass index (BMI, kg m⁻²; in fourths), physical activity (inactive, moderately inactive and active) (Friedenreich et al, 2007) (we combined the ‘moderately active’ and ‘active’ categories), alcohol intake (0, 4–15, 16–39, ≥40 g per day), marital status (married/cohabiting or not married/cohabiting) and education level (primary or none, secondary and degree level). For each of these variables a small proportion of values was unknown; these values were included in the analyses as a separate category.

Likelihood ratio χ²-tests were used to examine the heterogeneity of the associations of phyto-oestrogen concentrations with risk of prostate cancer categorised according to prostate tumour stage (localised or advanced), histologic grade (low grade or high grade) and time to diagnosis (<4 years after blood collection, ≥4 years after blood collection). Likelihood ratio χ²-tests were also used to examine the heterogeneity of the associations of phyto-oestrogens with prostate cancer risk for participants categorised by age at blood collection (<60 or ≥60 years) and by country of recruitment (eight countries).

RESULTS

Nine hundred and fifty men diagnosed with prostate cancer from recruitment until the end of follow-up and 1042 matched participants without prostate cancer were included in the analyses. Their median age at blood collection was 60 years (range 43–76 years).

When the characteristics of case patients and control participants were compared, the groups did not differ appreciably in most respects, but there were some small differences (Table 1). Compared with control participants, case patients had a slightly lower mean weight (80.1 and 81.1 kg, respectively) and lower mean BMI (26.6 and 26.8 kg m⁻², respectively), were less likely to be current smokers (24.3 and 28.7%, respectively), and were less likely to be physically active (43.7 and 49.3%, respectively).

Prostate cancer diagnosis followed blood collection by a median of 4.2 years (range <1–15.1 years) and the median age at diagnosis was 65 years (range 47–82 years).

Correlations between the plasma concentrations of the individual phyto-oestrogens among control participants were strongest between genistein and daidzein (r = 0.71, P < 0.001) and between the lignans, enterolactone and enterodiol (r = 0.38, P < 0.001). Genistein and daidzein were weakly correlated with the lignans (r = 0.08–0.19). Plasma concentrations of equol were not significantly correlated with the concentrations of any of the other analytes.

Table 2 shows median plasma concentrations of genistein, daidzein, equol, enterolactone and enterodiol, with 5th to 95th percentiles, in study controls, overall and in the eight countries participating in the study. There was substantial variation in the median concentrations between the countries, with participants in the United Kingdom and the Netherlands generally having the highest levels of isoflavones and participants in Denmark having the highest levels of lignans.

Table 3 shows the median plasma concentrations of genistein, daidzein, equol, enterolactone and enterodiol in case patients and control participants. The only weighted paired t-test of the differences between cases and controls that was statistically significant was for genistein (median concentrations 1.8 and 2.1 ng ml⁻¹, respectively, P = 0.007).

Table 4 shows the RRs for prostate cancer by plasma phyto-oestrogen concentration. There was a statistically significant inverse association between genistein and risk for prostate cancer;
comparing with the men in the lowest fifth of genistein concentration, men in the highest fifth had a RR of disease of 0.71 (95% confidence interval (CI) 0.53, 0.96; P linear trend = 0.032). When the analysis was repeated, additionally adjusting for smoking, BMI, physical activity, alcohol intake, marital status and education level, this association was borderline statistically significant (RR: 0.74, 95% CI 0.54, 1.00; P linear trend = 0.051). We observed no statistically significant association between risk for prostate cancer and the concentrations of daidzein, equol, enterolactone or enterodiol, with or without adjustment for potential confounders. There was no statistical evidence of heterogeneity in the trends in risk for prostate cancer according to the age of the men at blood collection, nor by country of recruitment. Neither there was statistical evidence of heterogeneity in the associations of phyto-oestrogen concentrations with risk of prostate cancer categorised according to prostate tumour stage, histological grade or time to diagnosis (data not shown).

**DISCUSSION**

In this first large prospective study, higher plasma concentrations of genistein were associated with a lower risk of prostate cancer. Risk for prostate cancer did not vary significantly by plasma concentration of daidzein or equol or by plasma concentrations of the lignans, enterolactone and enterodiol.

The design of this study offers several methodological advantages. The direct measurement of phyto-oestrogen concentrations in the circulation makes it possible to capture phyto-oestrogen exposure from all sources, including those that may be inadequately represented in food composition databases. For example, although the most abundant sources of isoflavones in the diet are soy foods, such as tofu and soymilk, the intake of which is low but variable across the European countries in EPIC (Keinan-Boker et al., 2002), soy additives are now also found in an increasing range of processed foods (Liggins et al., 2002). Isoflavones are also present in certain other vegetables, fruits and nuts (Liggins et al., 2000a, b), although in much lower concentrations than in soy foods. We were also able to assess exposure to specific phyto-oestrogens, which is particularly important as individual phyto-oestrogens have been found to differ in their biological activity, (Magee and Rowland, 2004) and the phyto-oestrogens absorbed through the intestine are dependent not only on dietary intake of phyto-oestrogens and their precursors, but also on the activity of intestinal bacteria that metabolise phyto-oestrogens (Rowland et al., 2003). Further strengths of this study include the large sample size and the varied dietary habits of the study population, linked with variation in plasma phyto-oestrogen levels across the different countries participating in the study (Peeters et al., 2007).

Our findings for plasma genistein are consistent with the findings from one small prospective study on circulating concentrations of isoflavones and prostate cancer, which found a non-significant dose-dependent reduction in risk in relation to concentrations of genistein among 40 men with prostate cancer and 101 without prostate cancer from the Japanese Collaborative Cohort Study (Ozasa et al., 2004). The only other published studies we are aware of are the EPIC-Nordic analyses of a total of 193 men with prostate cancer, 141 of whom are included in this study (Low et al., 2006; Ward et al., 2008), in which no associations were found between serum levels of phyto-oestrogens and risk of prostate cancer. Findings from the Japanese study (Ozasa et al., 2004) also suggested a modest and non-significant reduction in risk in relation to daidzein, which is consistent with the non-significant reduction in this study. This possible relationship may be a consequence of the association between genistein and risk, given the close correlation between circulating concentrations of these isoflavones. The findings from this study for equol, a metabolite of daidzein formed by microflora in the intestine, are in accordance with data from the Japanese study, which suggested no significant association (Ozasa et al., 2004). However, we have limited power in this study to assess the relationship among our study participants, as a high proportion of participants had negligible circulating
levels of equol, probably reflecting the fact that exposure to equol is dependent on both the consumption of daidzein and on being an ‘equol-producer’; ~30–50% of individuals do not excrete equol when challenged daily with soy foods (Setchell et al., 2002).

The findings from this study do not support the hypothesis that circulating lignans play a major role in the pathogenesis of prostate cancer, and are in agreement with results from the five earlier published prospective studies of circulating concentrations of enterolactone in relation to risk for prostate cancer (Stattin et al., 2000; Kilikkinen et al., 2004; Low et al., 2006; Ward et al., 2008).

Our finding of a possible protective association of genistein with prostate cancer risk is consistent with the experimental data from in vivo and in vitro studies (Bingham et al., 1998; Bylund et al., 2000; Goetzl et al., 2007). This association may be mediated by oestrogenic and/or a number of anti-carcinogenic properties, although the biological effects of exposure to phyto-oestrogens in humans remain uncertain (Bingham et al., 1998; Magee and Rowland, 2004; McCann et al., 2005; McCormick et al., 2007). Phyto-oestrogens have a structure similar to mammalian oestrogen, and can bind to the oestrogen receptor (Morito et al., 2001; Mueller et al., 2004). Experimental evidence suggests that the interaction of isoflavones with the oestrogen receptor beta (ER-β) might be particularly important in the development of prostate cancer (Morito et al., 2001; McCarty, 2006); compared with daidzein, genistein has a much greater affinity for the ER-β, selectively promoting ER-β signalling which in turn may suppress cellular proliferation and promote differentiation in the prostate (McCarty, 2006; Ricke et al., 2007). It is unclear though whether the levels of dietary phyto-oestrogen exposure in humans are sufficiently high to exert a biological effect (Liggins et al., 2000b; McCarty, 2006). The median circulating genistein concentration in the top fifth of the distribution in this study, 14 ng ml⁻¹, is approximately seven times lower than the average concentration of 87 ng ml⁻¹ for cases and 99 ng ml⁻¹ for controls found in the study of Japanese men (Ozasa et al., 2004). However, despite these lower levels of phyto-oestrogens we found some evidence of an association with prostate cancer risk.

We found no strong evidence for heterogeneity in the relationship of plasma phyto-oestrogens with prostate cancer risk by age at blood collection. These findings are consistent with an earlier study, which found no significant associations after stratifying by age (Stattin et al., 2004).

In this study, we were able to evaluate whether risk for prostate cancer in relation to circulating phyto-oestrogen concentrations varied by tumour characteristic. We found no evidence for a difference in the relationship between plasma phyto-oestrogens

### Table 4

Relative risk for prostate cancer by fifth of plasma phyto-oestrogen concentration.

<table>
<thead>
<tr>
<th>Fifth of phyto-oestrogen</th>
<th>1 (reference)</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>P for trend</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Isoflavones</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genistein</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range (ng ml⁻¹)</td>
<td>0.05–0.30</td>
<td>0.40–1.40</td>
<td>1.50–2.80</td>
<td>2.90–6.90</td>
<td>7.00–567.70</td>
<td></td>
</tr>
<tr>
<td>Cases/controls</td>
<td>217/219</td>
<td>205/209</td>
<td>171/201</td>
<td>185/205</td>
<td>172/208</td>
<td>0.032</td>
</tr>
<tr>
<td>RR (95% CI)</td>
<td>1 (reference)</td>
<td>0.95 (0.72–1.26)</td>
<td>0.79 (0.59–1.06)</td>
<td>0.80 (0.59–1.08)</td>
<td>0.71 (0.53–0.96)</td>
<td>0.032</td>
</tr>
<tr>
<td>Adjusted RR (95% CI)</td>
<td>1 (reference)</td>
<td>1.00 (0.76–1.34)</td>
<td>0.81 (0.60–1.10)</td>
<td>0.80 (0.59–1.08)</td>
<td>0.74 (0.54–1.00)</td>
<td>0.051</td>
</tr>
<tr>
<td><strong>Daidzein</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range (ng ml⁻¹)</td>
<td>0.05–0.30</td>
<td>0.40–0.70</td>
<td>0.80–1.70</td>
<td>1.80–4.00</td>
<td>4.10–194.70</td>
<td></td>
</tr>
<tr>
<td>Cases/controls</td>
<td>237/245</td>
<td>140/178</td>
<td>212/215</td>
<td>173/199</td>
<td>188/205</td>
<td></td>
</tr>
<tr>
<td>RR (95% CI)</td>
<td>1 (reference)</td>
<td>0.79 (0.59–1.06)</td>
<td>0.93 (0.71–1.22)</td>
<td>0.79 (0.59–1.05)</td>
<td>0.82 (0.62–1.09)</td>
<td>0.368</td>
</tr>
<tr>
<td>Adjusted RR (95% CI)</td>
<td>1 (reference)</td>
<td>0.77 (0.57–1.05)</td>
<td>0.94 (0.71–1.24)</td>
<td>0.75 (0.56–1.02)</td>
<td>0.80 (0.60–1.07)</td>
<td>0.209</td>
</tr>
<tr>
<td><strong>Equol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range (ng ml⁻¹)</td>
<td>0.05–0.05</td>
<td>0.10–0.20</td>
<td>0.30–0.40</td>
<td>0.50–0.70</td>
<td>0.80–41.30</td>
<td></td>
</tr>
<tr>
<td>Cases/controls</td>
<td>397/458</td>
<td>188/135</td>
<td>173/199</td>
<td>108/126</td>
<td>84/121</td>
<td></td>
</tr>
<tr>
<td>RR (95% CI)</td>
<td>1 (reference)</td>
<td>1.27 (0.98–1.63)</td>
<td>1.34 (1.03–1.76)</td>
<td>1.15 (0.84–1.58)</td>
<td>1.01 (0.72–1.41)</td>
<td>0.926</td>
</tr>
<tr>
<td>Adjusted RR (95% CI)</td>
<td>1 (reference)</td>
<td>1.24 (0.96–1.61)</td>
<td>1.34 (1.01–1.77)</td>
<td>1.11 (0.81–1.54)</td>
<td>0.99 (0.70–1.39)</td>
<td>0.461</td>
</tr>
<tr>
<td><strong>Lignans</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enterolactone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range (ng ml⁻¹)</td>
<td>0.05–1.40</td>
<td>1.50–2.90</td>
<td>3.00–4.80</td>
<td>4.90–9.30</td>
<td>9.40–149.30</td>
<td></td>
</tr>
<tr>
<td>Cases/controls</td>
<td>202/209</td>
<td>196/212</td>
<td>153/207</td>
<td>223/208</td>
<td>176/206</td>
<td></td>
</tr>
<tr>
<td>RR (95% CI)</td>
<td>1 (reference)</td>
<td>0.97 (0.74–1.27)</td>
<td>0.76 (0.57–1.02)</td>
<td>1.12 (0.85–1.47)</td>
<td>0.88 (0.66–1.17)</td>
<td>0.673</td>
</tr>
<tr>
<td>Adjusted RR (95% CI)</td>
<td>1 (reference)</td>
<td>0.93 (0.71–1.23)</td>
<td>0.71 (0.53–0.96)</td>
<td>1.03 (0.78–1.36)</td>
<td>0.77 (0.57–1.04)</td>
<td>0.92</td>
</tr>
<tr>
<td>Enterodiol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range (ng ml⁻¹)</td>
<td>0.05–0.10</td>
<td>0.20–0.20</td>
<td>0.30–0.40</td>
<td>0.50–0.90</td>
<td>1.00–46.40</td>
<td></td>
</tr>
<tr>
<td>Cases/controls</td>
<td>329/349</td>
<td>114/127</td>
<td>150/183</td>
<td>172/183</td>
<td>185/200</td>
<td></td>
</tr>
<tr>
<td>RR (95% CI)</td>
<td>1 (reference)</td>
<td>0.97 (0.72–1.31)</td>
<td>0.88 (0.67–1.15)</td>
<td>0.97 (0.74–1.27)</td>
<td>0.93 (0.71–1.22)</td>
<td>0.774</td>
</tr>
<tr>
<td>Adjusted RR (95% CI)</td>
<td>1 (reference)</td>
<td>0.99 (0.72–1.34)</td>
<td>0.86 (0.65–1.14)</td>
<td>0.97 (0.73–1.27)</td>
<td>0.88 (0.67–1.16)</td>
<td>0.293</td>
</tr>
</tbody>
</table>

BMI = body mass index; CI = confidence interval; RR = relative risk. Case patients and control participants were matched on recruitment centre, age at enrolment (± 6 months), time of day of blood collection (± 1 h), follow-up time (as close as possible), time between blood draw and last consumption of food or drinks (3h), marital status (married or cohabiting, not married or cohabiting), education (primary or none, secondary and degree level) and BMI (fourths). Adjustments were made for smoking (never, past and present), physical activity (inactive, moderately inactive and active), alcohol intake (<3, 3–6, >6 g per day), marital status (married or cohabiting, not married or cohabiting), education (primary or none, secondary and degree level) and BMI (fourths). Adjusted RR for equol, given the high proportion of values below the lower limit of detection and the interest in the comparison between non-producers and producers of equol, the grouping was as follows: non-detected (non-producers) and those with detectable levels of equol (producers) divided into four groups using the following cut-points, 0.30, 0.50 and 0.80 ng ml⁻¹.
and prostate cancer risk by stage or histological grade of the disease. These results are consistent with the findings from two other studies, which also reported no association of circulating enterolactone concentrations with localised or with advanced stage disease (Stattin et al., 2002, 2004; Kilkkinen et al., 2003). To our knowledge, no earlier published prospective studies have reported results for prediagnostic concentrations of circulating isoflavones in relation to prostate cancer risk stratified by tumour characteristics. The conclusions that can be drawn from this study, however, are limited by the small numbers in each category of tumour character, as shown by the width of the CIs.

The findings from this large prospective study in European men suggest that higher concentrations of circulating genistein are associated with a lower risk for prostate cancer. No evidence was found for a protective association with plasma lignans. Further large prospective analyses, and ultimately pooled analyses, are needed to confirm this apparent association with genistein concentration and to examine associations between the circulating phyto-oestrogen concentrations and prostate cancer subtypes. Given that the only established risk factors for the disease (age, family history and ethnicity) are not amenable to modification, the possible protective effect of genistein could offer an opportunity for the development of a preventative intervention.

ACKNOWLEDGEMENTS

We thank the participants in the EPIC study, Carine Beissy and Bertrand Hémon at IARC and Laure Dossus at DKFZ for their expertise in data handling, and Philip Grace at HFL for laboratory analyses. This study was sponsored by grants from Cancer Research UK; European Commission: Public Health and Consumer Protection Directorate 1993 – 2004; Research Directorate-General 2005; German Cancer Aid; German Cancer Research Center; German Federal Ministry of Education and Research; Danish Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of Health; ISCIII Red de Centros RCESP C03/09, Spain; Spanish Regional Governments of Andalusia, Asturia, Basque country, Murcia, and Navarra; Medical Research Council, UK; the Stroke Association, UK; British Heart Foundation; Department of Health, UK; Food Standards Agency, UK; the Wellcome Trust, UK; Greek Ministry of Health; Greek Ministry of Education; Italian Association for Research on Cancer (AIRC); Dutch Ministry of Public Health, Welfare and Sports; Dutch Ministry of Health; Dutch Prevention Funds; LK Research Funds; Dutch ZON (Zorg Onderzoek Nederland). The sponsors had no role in the study design, data collection, analysis, interpretation of results or writing of the paper.

REFERENCES


Peeters PH, Slimani N, van der Schouw YT, Grace PB, Navarro C, Tjonneland A, Olsen A, Clavel-Chapelon F, Touillaud M, Bouton-Ruault


StataCorp (2005) *Stata Statistical Software: Release 9*. StataCorp LP: College Station, TX


This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/.